Jim Simons Arbutus Biopharma Corp Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$2.24 - $3.06 $103,346 - $141,179	46,137 Added 16.78%	321,128 $739,000
Q1 2023 May 12, 2023	BUY	$2.23 - $3.1 $534,876 - $743,550	239,855 Added 682.65%	274,991 $833,000
Q4 2022 Feb 13, 2023	SELL	$1.91 - $2.85 $20,100 - $29,993	-10,524 Reduced 23.05%	35,136 $82,000
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $85,840 - $131,500	45,660 New	45,660 $87,000
Q2 2021 Aug 13, 2021	SELL	$2.5 - $3.51 $2.51 Million - $3.53 Million	-1,004,500 Closed	0 $0

Q1 2021 May 13, 2021	BUY	$3.14 - $4.84 $1.78 Million - $2.74 Million	566,537 Added 129.36%	1,004,500 $3.35 Million
Q4 2020 Feb 10, 2021	BUY	$2.76 - $4.97 $1.21 Million - $2.18 Million	437,963 New	437,963 $1.56 Million
Q3 2020 Nov 13, 2020	SELL	$1.75 - $6.2 $107,112 - $379,483	-61,207 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$0.91 - $2.36 $55,698 - $144,448	61,207 New	61,207 $111,000
Q4 2019 Feb 13, 2020	SELL	$0.87 - $2.89 $146,431 - $486,421	-168,312 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$1.34 - $2.4 $13,249 - $23,731	-9,888 Reduced 5.55%	168,312 $257,000
Q2 2019 Aug 12, 2019	BUY	$1.46 - $4.44 $260,172 - $791,208	178,200 New	178,200 $371,000

130

82.2M

4.82M

546K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $468M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.